Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Accendra Health (ACH) Payables (2016 - 2025)

Historic Payables for Accendra Health (ACH) over the last 17 years, with Q3 2025 value amounting to $339.7 million.

  • Accendra Health's Payables fell 7460.97% to $339.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.7 million, marking a year-over-year decrease of 7460.97%. This contributed to the annual value of $359.9 million for FY2024, which is 6928.64% down from last year.
  • As of Q3 2025, Accendra Health's Payables stood at $339.7 million, which was down 7460.97% from $357.0 million recorded in Q2 2025.
  • Accendra Health's Payables' 5-year high stood at $1.4 billion during Q2 2024, with a 5-year trough of $339.7 million in Q3 2025.
  • Over the past 5 years, Accendra Health's median Payables value was $1.1 billion (recorded in 2022), while the average stood at $1.0 billion.
  • Per our database at Business Quant, Accendra Health's Payables soared by 3667.18% in 2021 and then crashed by 7460.97% in 2025.
  • Accendra Health's Payables (Quarter) stood at $1.0 billion in 2021, then increased by 14.52% to $1.1 billion in 2022, then grew by 2.13% to $1.2 billion in 2023, then crashed by 69.29% to $359.9 million in 2024, then decreased by 5.61% to $339.7 million in 2025.
  • Its Payables stands at $339.7 million for Q3 2025, versus $357.0 million for Q2 2025 and $1.4 billion for Q1 2025.